Profound Medical (NASDAQ:PROF; TSX:PRN) appointed financial executive, Murielle Lortie, as a director, effective immediately.
Ms. Lortie is the CFO of Liminal Biosciences, a Nasdaq-listed, clinical-stage biopharmaceutical company. She was previously VP, CFO and advisor to the CEO at Pharmascience; and held senior positions in finance at Bristol Myers Squibb.
In a statement, Arun Menawat, Ph.D., Profound’s CEO and chairman, said “I am very pleased to welcome [Ms. Lortie] to our team. She is not only an experienced executive in the life science industry, but also has a breadth of relevant public company and board experience that should be invaluable as Profound executes the next stages of its growth strategy.”
